CME Activities
CLICK ON STATES TO SEE GRAND ROUNDS ACTIVITIES
ONLINE PROGRAMS
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below the Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
FACULTY
 Peter A. Lio, MD Clinical Assistant Professor Dermatology and Pediatrics Northwestern University Feinberg School of Medicine Medical Dermatology Associates of Chicago Founding Director, Chicago Integrative Eczema Center Chicago, IL |  Jacob P. Thyssen, MD, PhD, DMSci Clinical Dermatologist Department of Dermatology and Venereology Bispebjerg Hospital University of Copenhagen Copenhagen, Denmark |
PROGRAM OVERVIEW
This case-based activity will cover the underlying causes of atopic dermatitis along with current and emerging systemic agents as part of the overall treatment plan.
TARGET AUDIENCE
This activity is intended for dermatologists, allergists, nurse practitioners, physician assistants, and other healthcare professionals involved in the care and treatment of patients with atopic dermatitis.
LEARNING OBJECTIVES
- Incorporate patient-reported outcomes on the physical, mental, and social impact of AD on patient’s QoL into the selection of treatment options and the evaluation of therapeutic outcomes
- Assess the disease severity of atopic dermatitis and individualize treatment regimens to minimize disease burden, including itch and skin pain
- Apply knowledge of the mechanism of action of approved and emerging systemic agents and of clinical trial data on their efficacy and safety to the management of moderate-to-severe atopic dermatitis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 1.5 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the therapeutic management of patients with atopic dermatitis.
CNE Credits: 1.5 ANCC Contact Hour(s).
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Peter A. Lio, MD has served on the advisory board for the National Eczema Association, Modernizing Medicine, Johnson & Johnson, DermTap Inc., IntraDerm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Syncere Skin Systems, Dermveda, GPower Inc., UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Verrica Pharmaceuticals Inc., Arbonne, Yobee Care Inc., and Bodewell. Dr. Lio is a stockholder in Micreos, Altus Labs, Modernizing Medicine, LearnHealth/LearnSkin, and Medable. He has been a speaker for Pierre Fabre Dermatologie, Regeneron/Sanofi Genzyme, Pfizer Inc., Galderma, and La Roche-Posay. He has been an investigator for La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis), AOBiome LLC, Regeneron, AbbVie, and National Eczema Association. He has been a consultant for Regeneron/Sanofi Genzyme, Pfizer Inc., La Roche Posay, Pierre-Fabre, Level-Ex, Menlo, IntraDerm, Franklin/Altus, Galderma, Verrica, Arbonne, Bodewell, AOBiome, Realm, Exeltis, Theraplex, Odeza LLC, L’Oréal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Eli Lilly and Co., Unilever, Dermira, TopMD, Amyris Inc., Leo Pharma, and Burt’s Bees. Dr. Lio is a patent holder for Theraplex AIM product.
Jacob P Thyssen, MD, PhD, DMSci is a speaker, advisory board member, and/or investigator for Regeneron, Sanofi-Genzyme, Eli Lilly and Co, Pfizer, LEO Pharma, and AbbVie.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Director of Medical and Scientific Services, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures;
- Participate in the activity; and
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: April 8, 2021
EXPIRATION DATE: April 8, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected].
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.
VIRTUAL SUMMIT MEETINGS
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below the Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
FACULTY
Peter A. Lio, MD Clinical Assistant Professor Dermatology and Pediatrics Northwestern University Feinberg School of Medicine Medical Dermatology Associates of Chicago Founding Director, Chicago Integrative Eczema Center Chicago, IL | Jacob P. Thyssen, MD, PhD, DMSci Clinical Dermatologist Department of Dermatology and Venereology Bispebjerg Hospital University of Copenhagen Copenhagen, Denmark |
PROGRAM OVERVIEW
This case-based activity will cover the underlying causes of atopic dermatitis along with current and emerging systemic agents as part of the overall treatment plan.
TARGET AUDIENCE
This activity is intended for dermatologists, allergists, nurse practitioners, physician assistants, and other healthcare professionals involved in the care and treatment of patients with atopic dermatitis.
LEARNING OBJECTIVES
- Incorporate patient-reported outcomes on the physical, mental, and social impact of AD on patient’s QoL into the selection of treatment options and the evaluation of therapeutic outcomes
- Assess the disease severity of atopic dermatitis and individualize treatment regimens to minimize disease burden, including itch and skin pain
- Apply knowledge of the mechanism of action of approved and emerging systemic agents and of clinical trial data on their efficacy and safety to the management of moderate-to-severe atopic dermatitis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 1.5 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the therapeutic management of patients with atopic dermatitis.
CNE Credits: 1.5 ANCC Contact Hour(s).
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Peter A. Lio, MD has served on the advisory board for the National Eczema Association, Modernizing Medicine, Johnson & Johnson, DermTap Inc., IntraDerm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Syncere Skin Systems, Dermveda, GPower Inc., UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Verrica Pharmaceuticals Inc., Arbonne, Yobee Care Inc., and Bodewell. Dr. Lio is a stockholder in Micreos, Altus Labs, Modernizing Medicine, LearnHealth/LearnSkin, and Medable. He has been a speaker for Pierre Fabre Dermatologie, Regeneron/Sanofi Genzyme, Pfizer Inc., Galderma, and La Roche-Posay. He has been an investigator for La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis), AOBiome LLC, Regeneron, AbbVie, and National Eczema Association. He has been a consultant for Regeneron/Sanofi Genzyme, Pfizer Inc., La Roche Posay, Pierre-Fabre, Level-Ex, Menlo, IntraDerm, Franklin/Altus, Galderma, Verrica, Arbonne, Bodewell, AOBiome, Realm, Exeltis, Theraplex, Odeza LLC, L’Oréal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Eli Lilly and Co., Unilever, Dermira, TopMD, Amyris Inc., Leo Pharma, and Burt’s Bees. Dr. Lio is a patent holder for Theraplex AIM product.
Jacob P Thyssen, MD, PhD, DMSci is a speaker, advisory board member, and/or investigator for Regeneron, Sanofi-Genzyme, Eli Lilly and Co, Pfizer, LEO Pharma, and AbbVie.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Director of Medical and Scientific Services, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures;
- Participate in the activity; and
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: April 8, 2021
EXPIRATION DATE: April 8, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected].
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.
GRAND ROUNDS
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below The Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
Below the Surface: Managing the Physical, Mental, and Social Impact of Moderate-to-Severe Atopic Dermatitis
FACULTY
Peter A. Lio, MD Clinical Assistant Professor Dermatology and Pediatrics Northwestern University Feinberg School of Medicine Medical Dermatology Associates of Chicago Founding Director, Chicago Integrative Eczema Center Chicago, IL | Jacob P. Thyssen, MD, PhD, DMSci Clinical Dermatologist Department of Dermatology and Venereology Bispebjerg Hospital University of Copenhagen Copenhagen, Denmark |
PROGRAM OVERVIEW
This case-based activity will cover the underlying causes of atopic dermatitis along with current and emerging systemic agents as part of the overall treatment plan.
TARGET AUDIENCE
This activity is intended for dermatologists, allergists, nurse practitioners, physician assistants, and other healthcare professionals involved in the care and treatment of patients with atopic dermatitis.
LEARNING OBJECTIVES
- Incorporate patient-reported outcomes on the physical, mental, and social impact of AD on patient’s QoL into the selection of treatment options and the evaluation of therapeutic outcomes
- Assess the disease severity of atopic dermatitis and individualize treatment regimens to minimize disease burden, including itch and skin pain
- Apply knowledge of the mechanism of action of approved and emerging systemic agents and of clinical trial data on their efficacy and safety to the management of moderate-to-severe atopic dermatitis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 1.5 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the therapeutic management of patients with atopic dermatitis.
CNE Credits: 1.5 ANCC Contact Hour(s).
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Peter A. Lio, MD has served on the advisory board for the National Eczema Association, Modernizing Medicine, Johnson & Johnson, DermTap Inc., IntraDerm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Syncere Skin Systems, Dermveda, GPower Inc., UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Verrica Pharmaceuticals Inc., Arbonne, Yobee Care Inc., and Bodewell. Dr. Lio is a stockholder in Micreos, Altus Labs, Modernizing Medicine, LearnHealth/LearnSkin, and Medable. He has been a speaker for Pierre Fabre Dermatologie, Regeneron/Sanofi Genzyme, Pfizer Inc., Galderma, and La Roche-Posay. He has been an investigator for La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis), AOBiome LLC, Regeneron, AbbVie, and National Eczema Association. He has been a consultant for Regeneron/Sanofi Genzyme, Pfizer Inc., La Roche Posay, Pierre-Fabre, Level-Ex, Menlo, IntraDerm, Franklin/Altus, Galderma, Verrica, Arbonne, Bodewell, AOBiome, Realm, Exeltis, Theraplex, Odeza LLC, L’Oréal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Eli Lilly and Co., Unilever, Dermira, TopMD, Amyris Inc., Leo Pharma, and Burt’s Bees. Dr. Lio is a patent holder for Theraplex AIM product.
Jacob P Thyssen, MD, PhD, DMSci is a speaker, advisory board member, and/or investigator for Regeneron, Sanofi-Genzyme, Eli Lilly and Co, Pfizer, LEO Pharma, and AbbVie.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Director of Medical and Scientific Services, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures;
- Participate in the activity; and
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: April 8, 2021
EXPIRATION DATE: April 8, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected].
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.
